Skip to main content
Top
Published in: Inflammation 2/2013

01-04-2013

p53 Contributes to Quercetin-Induced Apoptosis in Human Rheumatoid Arthritis Fibroblast-like Synoviocytes

Authors: Peng Xiao, Yingjie Hao, Xu Zhu, Xuejian Wu

Published in: Inflammation | Issue 2/2013

Login to get access

Abstract

In the present study, we sought to explore the mechanism of quercetin-induced apoptosis in rheumatoid arthritis fibroblast-like synoviocytes (RAFLSs). DNA fragmentation assay was used to detect quercetin-induced apoptosis in RAFLSs. The cleavages of caspase-3 and caspase-9 and the accumulation of cytosolic cytochrome C were measured by western blot in quercetin-treated RAFLSs. Mitochondrial membrane potential was tested by flow cytometry. Small interfering RNAs were used to knock down the expression of protein 53 (p53) and analyze the role of p53 in quercetin-induced apoptosis in RAFLSs. DNA fragmentation assay showed that quercetin dose-dependently elevated the apoptosis of RAFLSs, accompanying with enhanced caspase-3 and caspase-9 cleavages. Moreover, quercetin caused a concentration-dependent loss of mitochondrial membrane potential and cytochrome c release to cytosol and also decreased Bcl-2/Bax ratio, indicating that quercetin-induced apoptosis is through mitochondrial pathway. Quercetin also elevated p53 phosphorylation at ser15. Pretreatment with pifithrin-α, a p53 inhibitor, significantly diminished p53 phosphorylation at the concentration of 30 μM and abrogated quercetin-induced apoptosis in a dose-dependent manner. Quercetin-induced apoptosis was also significantly blocked by p53 silencing, further suggesting the involvement of p53 in quercetin-induced apoptosis in RAFLSs. Our study indicated that quercetin-induced apoptosis of RAFLSs is through mitochondrial pathway, in which p53 plays an important role.
Literature
1.
go back to reference Harris Jr., E.D., and Rheumatoid arthritis. 1990. Pathophysiology and implications for therapy. The New England Journal of Medicine 322: 1277–1289.PubMedCrossRef Harris Jr., E.D., and Rheumatoid arthritis. 1990. Pathophysiology and implications for therapy. The New England Journal of Medicine 322: 1277–1289.PubMedCrossRef
2.
go back to reference Tran, C.N., S.K. Lundy, and D.A. Fox. 2005. Synovial biology and T cells in rheumatoid arthritis. Pathophysiology 12: 183–189.PubMedCrossRef Tran, C.N., S.K. Lundy, and D.A. Fox. 2005. Synovial biology and T cells in rheumatoid arthritis. Pathophysiology 12: 183–189.PubMedCrossRef
3.
go back to reference Firestein, G.S. 2005. Immunologic mechanisms in the pathogenesis of rheumatoid arthritis. Journal of Clinical Rheumatology 11: S39–S44.PubMedCrossRef Firestein, G.S. 2005. Immunologic mechanisms in the pathogenesis of rheumatoid arthritis. Journal of Clinical Rheumatology 11: S39–S44.PubMedCrossRef
4.
go back to reference Gay, S., R.E. Gay, and W.J. Koopman. 1993. Molecular and cellular mechanisms or joint destruction in rheumatoid arthritis: two cellular mechanisms explain joint destruction? Annals of the Rheumatic Diseases 52: S39–S47.PubMedCrossRef Gay, S., R.E. Gay, and W.J. Koopman. 1993. Molecular and cellular mechanisms or joint destruction in rheumatoid arthritis: two cellular mechanisms explain joint destruction? Annals of the Rheumatic Diseases 52: S39–S47.PubMedCrossRef
5.
go back to reference Huber, L.C., O. Distler, I. Tamer, R.E. Gay, S. Gay, and T. Pap. 2006. Synovial fibroblasts: key players in rheumatoid arthritis. Rheumatology 45: 669–675.PubMedCrossRef Huber, L.C., O. Distler, I. Tamer, R.E. Gay, S. Gay, and T. Pap. 2006. Synovial fibroblasts: key players in rheumatoid arthritis. Rheumatology 45: 669–675.PubMedCrossRef
6.
go back to reference Pattacini, L., L. Boiardi, B. Casali, and C. Salvarani. 2010. Differential effects of anti-TNF-alpha drugs on fibroblast-like synoviocyte apoptosis. Rheumatology (Oxford, England) 49: 480–489.CrossRef Pattacini, L., L. Boiardi, B. Casali, and C. Salvarani. 2010. Differential effects of anti-TNF-alpha drugs on fibroblast-like synoviocyte apoptosis. Rheumatology (Oxford, England) 49: 480–489.CrossRef
7.
go back to reference Miyashita, T., A. Kawakami, M. Tamai, Y. Izumi, H. Mingguo, F. Tanaka, S. Abiru, K. Nakashima, N. Iwanaga, K. Aratake, M. Kamachi, K. Arima, H. Ida, K. Migita, T. Origuchi, S. Tagashira, F. Nishikaku, and K. Eguchi. 2003. Akt is an endogenous inhibitor toward tumor necrosis factor-related apoptosis inducing ligand-mediated apoptosis in rheumatoid synovial cells. Biochemical and Biophysical Research Communications 312: 397–404.PubMedCrossRef Miyashita, T., A. Kawakami, M. Tamai, Y. Izumi, H. Mingguo, F. Tanaka, S. Abiru, K. Nakashima, N. Iwanaga, K. Aratake, M. Kamachi, K. Arima, H. Ida, K. Migita, T. Origuchi, S. Tagashira, F. Nishikaku, and K. Eguchi. 2003. Akt is an endogenous inhibitor toward tumor necrosis factor-related apoptosis inducing ligand-mediated apoptosis in rheumatoid synovial cells. Biochemical and Biophysical Research Communications 312: 397–404.PubMedCrossRef
8.
go back to reference Palao, G., B. Santiago, M. Galindo, M. Pallá, J.C. Ramírez, and J.L. Pablos. 2004. Down-regulation of FLIP sensitizes rheumatoid synovial fibroblasts to Fas-mediated apoptosis. Arthritis and Rheumatism 50: 2803–2810.PubMedCrossRef Palao, G., B. Santiago, M. Galindo, M. Pallá, J.C. Ramírez, and J.L. Pablos. 2004. Down-regulation of FLIP sensitizes rheumatoid synovial fibroblasts to Fas-mediated apoptosis. Arthritis and Rheumatism 50: 2803–2810.PubMedCrossRef
9.
go back to reference Aupperle, K.R., D.L. Boyle, M. Hendrix, E.A. Seftor, N.J. Zvaifler, M. Barbosa, and G.S. Firestein. 1998. Regulation of synoviocyte proliferation, apoptosis, and invasion by the p53 tumor suppressor gene. The American Journal of Pathology 152: 1091–1098.PubMed Aupperle, K.R., D.L. Boyle, M. Hendrix, E.A. Seftor, N.J. Zvaifler, M. Barbosa, and G.S. Firestein. 1998. Regulation of synoviocyte proliferation, apoptosis, and invasion by the p53 tumor suppressor gene. The American Journal of Pathology 152: 1091–1098.PubMed
10.
go back to reference Chou, C.T., J.S. Yang, and M.R. Lee. 2001. Apoptosis in rheumatoid arthritis—expression of Fas, Fas-L, p53, and Bcl-2 in rheumatoid synovial tissues. The Journal of Pathology 193: 110–116.PubMedCrossRef Chou, C.T., J.S. Yang, and M.R. Lee. 2001. Apoptosis in rheumatoid arthritis—expression of Fas, Fas-L, p53, and Bcl-2 in rheumatoid synovial tissues. The Journal of Pathology 193: 110–116.PubMedCrossRef
11.
go back to reference Bae, S.C., W.J. Jung, E.J. Lee, R. Yu, and M.K. Sung. 2009. Effects of antioxidant supplements intervention on the level of plasma inflammatory molecules and disease severity of rheumatoid arthritis patients. Journal of the American College of Nutrition 28: 56–62.PubMed Bae, S.C., W.J. Jung, E.J. Lee, R. Yu, and M.K. Sung. 2009. Effects of antioxidant supplements intervention on the level of plasma inflammatory molecules and disease severity of rheumatoid arthritis patients. Journal of the American College of Nutrition 28: 56–62.PubMed
12.
go back to reference Jackson, J.K., T. Higo, W.L. Hunter, and H.M. Burt. 2006. The antioxidants curcumin and quercetin inhibit inflammatory processes associated with arthritis. Inflammation Research 55: 168–175.PubMedCrossRef Jackson, J.K., T. Higo, W.L. Hunter, and H.M. Burt. 2006. The antioxidants curcumin and quercetin inhibit inflammatory processes associated with arthritis. Inflammation Research 55: 168–175.PubMedCrossRef
13.
go back to reference Sato, M., T. Miyazaki, F. Kambe, K. Maeda, and H. Seo. 1997. Quercetin, a bioflavonoid, inhibits the induction of interleukin 8 and monocyte chemoattractant protein-1 expression by tumor necrosis factor-alpha in cultured human synovial cells. The Journal of Rheumatology 24: 1680–1684.PubMed Sato, M., T. Miyazaki, F. Kambe, K. Maeda, and H. Seo. 1997. Quercetin, a bioflavonoid, inhibits the induction of interleukin 8 and monocyte chemoattractant protein-1 expression by tumor necrosis factor-alpha in cultured human synovial cells. The Journal of Rheumatology 24: 1680–1684.PubMed
14.
go back to reference Choi, E.J., S.C. Bae, R. Yu, J. Youn, and M.K. Sung. 2009. Dietary vitamin E and quercetin modulate inflammatory responses of collagen-induced arthritis in mice. Journal of Medicinal Food 12: 770–775.PubMedCrossRef Choi, E.J., S.C. Bae, R. Yu, J. Youn, and M.K. Sung. 2009. Dietary vitamin E and quercetin modulate inflammatory responses of collagen-induced arthritis in mice. Journal of Medicinal Food 12: 770–775.PubMedCrossRef
15.
go back to reference Sung, M.S., E.G. Lee, H.S. Jeon, H.J. Chae, S.J. Park, Y.C. Lee, and W.H. Yoo. 2012. Quercetin inhibits IL-1β-induced proliferation and production of MMPs, COX-2, and PGE2 by rheumatoid synovial fibroblast. Inflammation 35: 1585–1594.PubMedCrossRef Sung, M.S., E.G. Lee, H.S. Jeon, H.J. Chae, S.J. Park, Y.C. Lee, and W.H. Yoo. 2012. Quercetin inhibits IL-1β-induced proliferation and production of MMPs, COX-2, and PGE2 by rheumatoid synovial fibroblast. Inflammation 35: 1585–1594.PubMedCrossRef
16.
go back to reference Ong, C.S., E. Tran, T.T. Nguyen, C.K. Ong, S.K. Lee, J.J. Lee, C.P. Ng, C. Leong, and H. Huynh. 2004. Quercetin-induced growth inhibition and cell death in nasopharyngeal carcinoma cells are associated with increase in Bad and hypophosphorylated retinoblastoma expressions. Oncology Reports 11: 727–733.PubMed Ong, C.S., E. Tran, T.T. Nguyen, C.K. Ong, S.K. Lee, J.J. Lee, C.P. Ng, C. Leong, and H. Huynh. 2004. Quercetin-induced growth inhibition and cell death in nasopharyngeal carcinoma cells are associated with increase in Bad and hypophosphorylated retinoblastoma expressions. Oncology Reports 11: 727–733.PubMed
17.
go back to reference Arnett, F.C., S.M. Edworthy, D.A. Bloch, D.J. McShane, J.F. Fries, N.S. Cooper, L.A. Healey, S.R. Kaplan, M.H. Liang, H.S. Luthra, et al. 1988. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis and Rheumatism 31: 315–324.PubMedCrossRef Arnett, F.C., S.M. Edworthy, D.A. Bloch, D.J. McShane, J.F. Fries, N.S. Cooper, L.A. Healey, S.R. Kaplan, M.H. Liang, H.S. Luthra, et al. 1988. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis and Rheumatism 31: 315–324.PubMedCrossRef
18.
go back to reference Brunelle, J.K., and A. Letai. 2009. Control of mitochondrial apoptosis by the Bcl-2 family. Journal of Cell Science 122: 437–441.PubMedCrossRef Brunelle, J.K., and A. Letai. 2009. Control of mitochondrial apoptosis by the Bcl-2 family. Journal of Cell Science 122: 437–441.PubMedCrossRef
19.
go back to reference Vaseva, A.V., and U.M. Moll. 2009. The mitochondrial p53 pathway. Biochimica et Biophysica Acta 1787: 414–420.PubMedCrossRef Vaseva, A.V., and U.M. Moll. 2009. The mitochondrial p53 pathway. Biochimica et Biophysica Acta 1787: 414–420.PubMedCrossRef
20.
go back to reference Zhao, H., F. Traganos, and Z. Darzynkiewicz. 2008. Phosphorylation of p53 on Ser15 during cell cycle caused by Topo I and Topo II inhibitors in relation to ATM and Chk2 activation. Cell Cycle 7: 3048–3055.PubMedCrossRef Zhao, H., F. Traganos, and Z. Darzynkiewicz. 2008. Phosphorylation of p53 on Ser15 during cell cycle caused by Topo I and Topo II inhibitors in relation to ATM and Chk2 activation. Cell Cycle 7: 3048–3055.PubMedCrossRef
21.
go back to reference Natarajan, V., N. Krithica, B. Madhan, and P.K. Sehgal. 2011. Formulation and evaluation of quercetin polycaprolactone microspheres for the treatment of rheumatoid arthritis. Journal of Pharmaceutical Sciences 100: 195–205.PubMedCrossRef Natarajan, V., N. Krithica, B. Madhan, and P.K. Sehgal. 2011. Formulation and evaluation of quercetin polycaprolactone microspheres for the treatment of rheumatoid arthritis. Journal of Pharmaceutical Sciences 100: 195–205.PubMedCrossRef
22.
go back to reference Choi, J.A., J.Y. Kim, J.Y. Lee, C.M. Kang, H.J. Kwon, Y.D. Yoo, T.W. Kim, Y.S. Lee, and S.J. Lee. 2001. Induction of cell cycle arrest and apoptosis in human breast cancer cells by quercetin. International Journal of Oncology 19: 837–844.PubMed Choi, J.A., J.Y. Kim, J.Y. Lee, C.M. Kang, H.J. Kwon, Y.D. Yoo, T.W. Kim, Y.S. Lee, and S.J. Lee. 2001. Induction of cell cycle arrest and apoptosis in human breast cancer cells by quercetin. International Journal of Oncology 19: 837–844.PubMed
23.
go back to reference Lee, T.J., O.H. Kim, Y.H. Kim, J.H. Lim, S. Kim, J.W. Park, and T.K. Kwon. 2006. Quercetin arrests G2/M phase and induces caspase-dependent cell death in U937 cells. Cancer Letters 240: 234–242.PubMedCrossRef Lee, T.J., O.H. Kim, Y.H. Kim, J.H. Lim, S. Kim, J.W. Park, and T.K. Kwon. 2006. Quercetin arrests G2/M phase and induces caspase-dependent cell death in U937 cells. Cancer Letters 240: 234–242.PubMedCrossRef
24.
go back to reference Jacquemin, G., V. Granci, A.S. Gallouet, N. Lalaoui, A. Morlé, E. Iessi, A. Morizot, C. Garrido, T. Guillaudeux, and O. Micheau. 2012. Quercetin-mediated Mcl-1 and survivin downregulation restores TRAIL-induced apoptosis in non-Hodgkin’s lymphoma B cells. Haematologica 97: 38–46.PubMedCrossRef Jacquemin, G., V. Granci, A.S. Gallouet, N. Lalaoui, A. Morlé, E. Iessi, A. Morizot, C. Garrido, T. Guillaudeux, and O. Micheau. 2012. Quercetin-mediated Mcl-1 and survivin downregulation restores TRAIL-induced apoptosis in non-Hodgkin’s lymphoma B cells. Haematologica 97: 38–46.PubMedCrossRef
25.
go back to reference Firestein, G.S., K. Nguyen, K.R. Aupperle, M. Yeo, D.L. Boyle, and N.J. Zvaifler. 1996. Apoptosis in rheumatoid arthritis: p53 overexpression in rheumatoid arthritis synovium. The American Journal of Pathology 149: 2143–2151.PubMed Firestein, G.S., K. Nguyen, K.R. Aupperle, M. Yeo, D.L. Boyle, and N.J. Zvaifler. 1996. Apoptosis in rheumatoid arthritis: p53 overexpression in rheumatoid arthritis synovium. The American Journal of Pathology 149: 2143–2151.PubMed
26.
go back to reference Redondo, A., N. Estrella, A.G. Lorenzo, M. Cruzado, and C. Castro. 2012. Quercetin and catechin synergistically inhibit angiotensin II-induced redox-dependent signalling pathways in vascular smooth muscle cells from hypertensive rats. Free Radical Research 46: 619–627.PubMedCrossRef Redondo, A., N. Estrella, A.G. Lorenzo, M. Cruzado, and C. Castro. 2012. Quercetin and catechin synergistically inhibit angiotensin II-induced redox-dependent signalling pathways in vascular smooth muscle cells from hypertensive rats. Free Radical Research 46: 619–627.PubMedCrossRef
27.
go back to reference Hwang, S.J., B. Choi, S.S. Kang, J.H. Chang, Y.G. Kim, Y.H. Chung, D.H. Sohn, M.W. So, C.K. Lee, W.H. Robinson, and E.J. Chang. 2012. Interleukin-34 produced by human fibroblast-like synovial cells in rheumatoid arthritis supports osteoclastogenesis. Arthritis Research & Therapy 14: R14.CrossRef Hwang, S.J., B. Choi, S.S. Kang, J.H. Chang, Y.G. Kim, Y.H. Chung, D.H. Sohn, M.W. So, C.K. Lee, W.H. Robinson, and E.J. Chang. 2012. Interleukin-34 produced by human fibroblast-like synovial cells in rheumatoid arthritis supports osteoclastogenesis. Arthritis Research & Therapy 14: R14.CrossRef
28.
go back to reference Lau, S.T., Z.X. Lin, and P.S. Leung. 2010. Role of reactive oxygen species in brucein D-mediated p38-mitogen-activated protein kinase and nuclear factor-kappaB signalling pathways in human pancreatic adenocarcinoma cells. British Journal of Cancer 102: 583–593.PubMedCrossRef Lau, S.T., Z.X. Lin, and P.S. Leung. 2010. Role of reactive oxygen species in brucein D-mediated p38-mitogen-activated protein kinase and nuclear factor-kappaB signalling pathways in human pancreatic adenocarcinoma cells. British Journal of Cancer 102: 583–593.PubMedCrossRef
Metadata
Title
p53 Contributes to Quercetin-Induced Apoptosis in Human Rheumatoid Arthritis Fibroblast-like Synoviocytes
Authors
Peng Xiao
Yingjie Hao
Xu Zhu
Xuejian Wu
Publication date
01-04-2013
Publisher
Springer US
Published in
Inflammation / Issue 2/2013
Print ISSN: 0360-3997
Electronic ISSN: 1573-2576
DOI
https://doi.org/10.1007/s10753-012-9543-5

Other articles of this Issue 2/2013

Inflammation 2/2013 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine